{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T18:48:13Z","timestamp":1790880493894,"version":"4.1.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,6,19]],"date-time":"2023-06-19T00:00:00Z","timestamp":1687132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,6,19]],"date-time":"2023-06-19T00:00:00Z","timestamp":1687132800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1007\/s00277-023-05306-2","type":"journal-article","created":{"date-parts":[[2023,6,19]],"date-time":"2023-06-19T07:02:35Z","timestamp":1687158155000},"page":"2127-2136","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Rituximab versus obinutuzumab-based first-line chemoimmunotherapy for follicular lymphoma\u2014a real-world multicenter retrospective cohort study"],"prefix":"10.1007","volume":"102","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5547-6936","authenticated-orcid":false,"given":"Tamar","family":"Berger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tzippy","family":"Shochat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shlomzion","family":"Aumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boaz","family":"Nachmias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neta","family":"Goldschmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nurit","family":"Horesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reut","family":"Harel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariel","family":"Aviv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ella","family":"Shmerts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uri","family":"Abadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shai","family":"Shimony","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pia","family":"Raanani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anat","family":"Gafter\u2011Gvili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronit","family":"Gurion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,19]]},"reference":[{"key":"5306_CR1","doi-asserted-by":"publisher","first-page":"443","DOI":"10.3322\/caac.21357","volume":"66","author":"LR Teras","year":"2016","unstructured":"Teras LR, DeSantis CE, Cerhan JR et al (2016) 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin 66:443\u2013459. https:\/\/doi.org\/10.3322\/caac.21357","journal-title":"CA Cancer J Clin"},{"key":"5306_CR2","first-page":"148","volume":"35","author":"E Dotan","year":"2010","unstructured":"Dotan E, Aggarwal C, Smith MR (2010) Impact of rituximab (rituxan) on the treatment of B-cell non-Hodgkin\u2019s lymphoma. P T 35:148\u2013157","journal-title":"P T"},{"key":"5306_CR3","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1093\/jnci\/djk152","volume":"99","author":"H Schulz","year":"2007","unstructured":"Schulz H, Bohlius JF, Trelle S et al (2007) Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst 99:706\u2013714. https:\/\/doi.org\/10.1093\/jnci\/djk152","journal-title":"J Natl Cancer Inst"},{"key":"5306_CR4","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1614598","volume":"377","author":"R Marcus","year":"2017","unstructured":"Marcus R, Davies A, Ando K et al (2017) Obinutuzumab for the first-line treatment of follicular lymphoma. N Engl J Med 377:1331\u20131344. https:\/\/doi.org\/10.1056\/NEJMoa1614598","journal-title":"N Engl J Med"},{"key":"5306_CR5","doi-asserted-by":"publisher","first-page":"8023","DOI":"10.1200\/JCO.2020.38.15_suppl.8023","volume":"38","author":"W Townsend","year":"2020","unstructured":"Townsend W, Buske C, Cartron G et al (2020) Comparison of efficacy and safety with obinutuzumab plus chemotherapy versus rituximab plus chemotherapy in patients with previously untreated follicular lymphoma: updated results from the phase III Gallium Study. JCO 38:8023\u20138023. https:\/\/doi.org\/10.1200\/JCO.2020.38.15_suppl.8023","journal-title":"JCO"},{"key":"5306_CR6","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1111\/bjh.16872","volume":"191","author":"C McNamara","year":"2020","unstructured":"McNamara C, Montoto S, Eyre TA et al (2020) The investigation and management of follicular lymphoma. Br J Haematol 191:363\u2013381. https:\/\/doi.org\/10.1111\/bjh.16872","journal-title":"Br J Haematol"},{"key":"5306_CR7","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.annonc.2020.11.008","volume":"32","author":"M Dreyling","year":"2021","unstructured":"Dreyling M, Ghielmini M, Rule S et al (2021) Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 32:298\u2013308. https:\/\/doi.org\/10.1016\/j.annonc.2020.11.008","journal-title":"Ann Oncol"},{"key":"5306_CR8","doi-asserted-by":"publisher","first-page":"63","DOI":"10.3109\/10428194.2015.1046862","volume":"57","author":"A Gafter-Gvili","year":"2016","unstructured":"Gafter-Gvili A, Ribakovsky E, Mizrahi N et al (2016) Infections associated with bendamustine containing regimens in hematological patients: a retrospective multi-center study. Leuk Lymphoma 57:63\u201369. https:\/\/doi.org\/10.3109\/10428194.2015.1046862","journal-title":"Leuk Lymphoma"},{"key":"5306_CR9","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.ajic.2008.03.002","volume":"36","author":"TC Horan","year":"2008","unstructured":"Horan TC, Andrus M, Dudeck MA (2008) CDC\/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 36:309\u2013332. https:\/\/doi.org\/10.1016\/j.ajic.2008.03.002","journal-title":"Am J Infect Control"},{"key":"5306_CR10","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.1093\/cid\/cir073","volume":"52","author":"AG Freifeld","year":"2011","unstructured":"Freifeld AG, Bow EJ, Sepkowitz KA et al (2011) Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 52:e56-93. https:\/\/doi.org\/10.1093\/cid\/cir073","journal-title":"Clin Infect Dis"},{"key":"5306_CR11","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.adengl.2019.05.021","volume":"112","author":"A Freites-Martinez","year":"2021","unstructured":"Freites-Martinez A, Santana N, Arias-Santiago S, Viera A (2021) Using the common terminology criteria for adverse events (CTCAE \u2013 version 5.0) to evaluate the severity of adverse events of anticancer therapies. Actas Dermo-Sifiliogr\u00e1ficas (English Edition) 112:90\u201392. https:\/\/doi.org\/10.1016\/j.adengl.2019.05.021","journal-title":"Actas Dermo-Sifiliogr\u00e1ficas (English Edition)"},{"key":"5306_CR12","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF et al (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32:3059\u20133068. https:\/\/doi.org\/10.1200\/JCO.2013.54.8800","journal-title":"J Clin Oncol"},{"key":"5306_CR13","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-022-04155-2","author":"G Claustre","year":"2022","unstructured":"Claustre G, Boulanger C, Maloisel F et al (2022) Comparative analysis of rituximab or obinutuzumab combined with CHOP in first-line treatment of follicular lymphoma. J Cancer Res Clin Oncol. https:\/\/doi.org\/10.1007\/s00432-022-04155-2","journal-title":"J Cancer Res Clin Oncol"},{"key":"5306_CR14","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1002\/hon.2828","volume":"39","author":"I Amitai","year":"2021","unstructured":"Amitai I, Gafter-Gvili A, Shargian-Alon L et al (2021) Obinutuzumab-related adverse events: a systematic review and meta-analysis. Hematol Oncol 39:215\u2013221. https:\/\/doi.org\/10.1002\/hon.2828","journal-title":"Hematol Oncol"},{"key":"5306_CR15","doi-asserted-by":"publisher","first-page":"2921","DOI":"10.1080\/10428194.2021.1948037","volume":"62","author":"S Shimony","year":"2021","unstructured":"Shimony S, Bar-Sever E, Berger T et al (2021) Late onset neutropenia after rituximab and obinutuzumab treatment - characteristics of a class-effect toxicity. Leuk Lymphoma 62:2921\u20132927. https:\/\/doi.org\/10.1080\/10428194.2021.1948037","journal-title":"Leuk Lymphoma"},{"key":"5306_CR16","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1182\/blood-2013-07-517037","volume":"123","author":"M Pfreundschuh","year":"2014","unstructured":"Pfreundschuh M, M\u00fcller C, Zeynalova S et al (2014) Suboptimal dosing of rituximab in male and female patients with DLBCL. Blood 123:640\u2013646. https:\/\/doi.org\/10.1182\/blood-2013-07-517037","journal-title":"Blood"},{"key":"5306_CR17","doi-asserted-by":"publisher","first-page":"e0038","DOI":"10.5041\/RMMJ.10172","volume":"5","author":"N Horesh","year":"2014","unstructured":"Horesh N, Horowitz NA (2014) Does gender matter in non-hodgkin lymphoma? Differences in epidemiology, clinical behavior, and therapy. Rambam Maimonides Med J 5:e0038. https:\/\/doi.org\/10.5041\/RMMJ.10172","journal-title":"Rambam Maimonides Med J"},{"key":"5306_CR18","doi-asserted-by":"publisher","first-page":"226","DOI":"10.3324\/haematol.2015.133421","volume":"101","author":"G Cartron","year":"2016","unstructured":"Cartron G, Hourcade-Potelleret F, Morschhauser F et al (2016) Rationale for optimal obinutuzumab\/GA101 dosing regimen in B-cell non-Hodgkin lymphoma. Haematologica 101:226\u2013234. https:\/\/doi.org\/10.3324\/haematol.2015.133421","journal-title":"Haematologica"},{"key":"5306_CR19","doi-asserted-by":"publisher","first-page":"741","DOI":"10.3855\/jidc.10399","volume":"12","author":"A Y\u0131ld\u0131z","year":"2018","unstructured":"Y\u0131ld\u0131z A, Albayrak M, Pala \u00c7 et al (2018) Infections in patients with lymphoma: an analysis of incidence, relationship and risk factors. J Infect Dev Ctries 12:741\u2013747. https:\/\/doi.org\/10.3855\/jidc.10399","journal-title":"J Infect Dev Ctries"},{"key":"5306_CR20","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1002\/hon.2350","volume":"35","author":"A Gafter-Gvili","year":"2017","unstructured":"Gafter-Gvili A, Gurion R, Raanani P et al (2017) Bendamustine-associated infections-systematic review and meta-analysis of randomized controlled trials. Hematol Oncol 35:424\u2013431. https:\/\/doi.org\/10.1002\/hon.2350","journal-title":"Hematol Oncol"},{"key":"5306_CR21","doi-asserted-by":"publisher","first-page":"559","DOI":"10.7326\/0003-4819-129-7-199810010-00010","volume":"129","author":"EJ Anaissie","year":"1998","unstructured":"Anaissie EJ, Kontoyiannis DP, O\u2019Brien S et al (1998) Infections in patients with chronic lymphocytic leukemia treated with fludarabine. Ann Intern Med 129:559\u2013566. https:\/\/doi.org\/10.7326\/0003-4819-129-7-199810010-00010","journal-title":"Ann Intern Med"},{"key":"5306_CR22","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1046\/j.1365-2141.2003.04497.x","volume":"122","author":"M Hensel","year":"2003","unstructured":"Hensel M, Kornacker M, Yammeni S et al (2003) Disease activity and pretreatment, rather than hypogammaglobulinaemia, are major risk factors for infectious complications in patients with chronic lymphocytic leukaemia. Br J Haematol 122:600\u2013606. https:\/\/doi.org\/10.1046\/j.1365-2141.2003.04497.x","journal-title":"Br J Haematol"},{"key":"5306_CR23","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","volume":"104","author":"P Solal-C\u00e9ligny","year":"2004","unstructured":"Solal-C\u00e9ligny P, Roy P, Colombat P et al (2004) Follicular lymphoma international prognostic index. Blood 104:1258\u20131265. https:\/\/doi.org\/10.1182\/blood-2003-12-4434","journal-title":"Blood"},{"key":"5306_CR24","doi-asserted-by":"publisher","first-page":"3384","DOI":"10.1080\/10428194.2021.1966782","volume":"62","author":"I Levy","year":"2021","unstructured":"Levy I, Lavi A, Zimran E et al (2021) COVID-19 among patients with hematological malignancies: a national Israeli retrospective analysis with special emphasis on treatment and outcome. Leuk Lymphoma 62:3384\u20133393. https:\/\/doi.org\/10.1080\/10428194.2021.1966782","journal-title":"Leuk Lymphoma"},{"key":"5306_CR25","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1182\/bloodadvances.2021005691","volume":"6","author":"C Visco","year":"2022","unstructured":"Visco C, Marcheselli L, Mina R et al (2022) A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study. Blood Adv 6:327\u2013338. https:\/\/doi.org\/10.1182\/bloodadvances.2021005691","journal-title":"Blood Adv"},{"key":"5306_CR26","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s13045-020-00970-7","volume":"13","author":"J Garc\u00eda-Su\u00e1rez","year":"2020","unstructured":"Garc\u00eda-Su\u00e1rez J, de la Cruz J, Cedillo \u00c1 et al (2020) Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: lessons from a large population-based registry study. J Hematol Oncol 13:133. https:\/\/doi.org\/10.1186\/s13045-020-00970-7","journal-title":"J Hematol Oncol"},{"key":"5306_CR27","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.exphem.2021.12.396","volume":"107","author":"A Tvito","year":"2022","unstructured":"Tvito A, Ronson A, Ghosheh R et al (2022) Anti-CD20 monoclonal antibodies inhibit seropositive response to Covid-19 vaccination in non-Hodgkin lymphoma patients within 6 months after treatment. Exp Hematol 107:20\u201323. https:\/\/doi.org\/10.1016\/j.exphem.2021.12.396","journal-title":"Exp Hematol"},{"key":"5306_CR28","doi-asserted-by":"publisher","first-page":"715","DOI":"10.3324\/haematol.2021.279216","volume":"107","author":"R Gurion","year":"2022","unstructured":"Gurion R, Rozovski U, Itchaki G et al (2022) Humoral serological response to the BNT162b2 vaccine is abrogated in lymphoma patients within the first 12 months following treatment with anti-CD2O antibodies. Haematologica 107:715\u2013720. https:\/\/doi.org\/10.3324\/haematol.2021.279216","journal-title":"Haematologica"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05306-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-023-05306-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05306-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,13]],"date-time":"2023-07-13T07:07:24Z","timestamp":1689232044000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-023-05306-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,19]]},"references-count":28,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["5306"],"URL":"https:\/\/doi.org\/10.1007\/s00277-023-05306-2","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,19]]},"assertion":[{"value":"3 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Approval was obtained from Rabin Medical Center (RMC) Institutional Review Board (IRB) ethics committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was waived due to the retrospective design of the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Tamar Berger\u2014Janseen (honoraria, advisory committee), Neopharm (advisory committee).Boaz Nachmias\u2014AbbVie (consultant, honoraria, research funding).Pia Raanani\u2014Pfizer (advisory board, consultancy, research support, speaker\u2019s bureau); Novartis (consultancy, research support); BMS (consultancy); Janssen (speaker\u2019s bureau).Ronit Gurion\u2014Roche, Gilead, Medison Ltd, Novartis, and Takeda (honoraria and advisory committee).All other authors have no relevant financial or non-financial interests to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}